Holen Sie sich die Stockscreener-App
1.89
2.16%
0.04
Handel nachbörslich:
1.86
-0.03
-1.59%
Schlusskurs vom Vortag:
$1.85
Offen:
$1.87
24-Stunden-Volumen:
347.03K
Relative Volume:
0.34
Marktkapitalisierung:
$112.24M
Einnahmen:
$30.91M
Nettoeinkommen (Verlust:
$-74.28M
KGV:
-1.5513
EPS:
-1.2183
Netto-Cashflow:
$-86.15M
1W Leistung:
-5.03%
1M Leistung:
-54.13%
6M Leistung:
-61.19%
1J Leistung:
-57.24%
1-Tages-Spanne:
$1.82
$1.91
1-Wochen-Bereich:
$1.80
$2.00
52-Wochen-Spanne:
$1.79
$7.61
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Firmenname
Foghorn Therapeutics Inc
Sektor
Branche
Telefon
617-586-3100
Adresse
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
1.89 | 112.24M | 30.91M | -74.28M | -86.15M | -1.2183 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-13 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2026-10-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-10-02 | Herabstufung | TD Cowen | Buy → Hold |
| 2026-10-02 | Herabstufung | Wedbush | Outperform → Neutral |
| 2026-02-17 | Fortgesetzt | Jefferies | Buy |
| 2025-12-18 | Eingeleitet | BTIG Research | Buy |
| 2025-11-07 | Eingeleitet | Guggenheim | Buy |
| 2025-09-17 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-04-23 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-01-30 | Eingeleitet | B. Riley Securities | Buy |
| 2024-09-03 | Eingeleitet | Jefferies | Buy |
| 2024-08-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-03-28 | Eingeleitet | BofA Securities | Buy |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-17 | Eingeleitet | Cowen | Outperform |
| 2020-11-17 | Eingeleitet | Goldman | Buy |
| 2020-11-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-11-17 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Foghorn Therapeutics Inc Aktie (FHTX) Neueste Nachrichten
Foghorn: Downgrade "Sell" Eli Lilly Exit FHD-909 And Shift To Preclinical Assets - Seeking Alpha
A more-than-10% owner reports $0.0001 warrants in Foghorn Therapeutics (FHTX). - Stock Titan
A 9.99% cap blocked warrant exercise as BVF reported a stake in Foghorn Therapeutics (FHTX). - Stock Titan
Today's US Stock Gap Movers: DAICW, NXL Lead Gap-Ups; FHTX Leads Gap-Downs - ChartMill
Guggenheim cuts Foghorn Therapeutics price target on drug setback By Investing.com - Investing.com South Africa
Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data - Pharmaceutical Executive
Foghorn Therapeutics stock price target cut to $5 by H.C. Wainwright on program halt - Investing.com
Foghorn Therapeutics stock price target cut to $5 by H.C. Wainwright on program halt - Investing.com Canada
Guggenheim cuts Foghorn Therapeutics price target on drug setback - Investing.com
Stifel cuts Foghorn Therapeutics stock price target on pipeline shift By Investing.com - Investing.com South Africa
Stifel cuts Foghorn Therapeutics stock price target on pipeline shift - Investing.com
Stifel cuts Foghorn Therapeutics stock price target on pipeline shift By Investing.com - Investing.com UK
Foghorn lays off 40% of staff after Lilly collaboration ends - biospace.com
Thursday's session: gap up and gap down stocks - ChartMill
FHTX Stock Slides As Traders Focus On Cash Runway And Charts - StocksToTrade
FHTX Stock Slides As Traders Eye Key Support Levels - timothysykes.com
FHTX Stock Slides As Traders Eye Key Support Levels - Timothy Sykes
Why is Foghorn Therapeutics stock plummeting today? - Investing.com
Citizens reiterates Foghorn Therapeutics stock rating on trial data - Investing.com
Foghorn Therapeutics (FHTX) Slips 2.17% to $5.87 as Shares Approach Key Support ZoneStock Buy Zone - dars.gov.et
What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Price to book forward of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingView
Precision Trading with Foghorn Therapeutics Inc. (FHTX) Risk Zones - Stock Traders Daily
Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet - Yahoo Finance
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 By Investing.com - Investing.com South Africa
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 - Investing.com
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 By Investing.com - Investing.com Canada
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 By Investing.com - Investing.com UK
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 - Investing.com
Foghorn Therapeutics (FHTX) Slips 3.5% as Shares Test Key Support Near $5.95Low Vol Factor - vinanet.vn
Foghorn Therapeutics (FHTX) Slips 3.5% as Shares Test Key Support Near $5.95NHNL Divergence - dars.gov.et
Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy - Yahoo Finance
Foghorn Therapeutics Inc.: Fundamental Analysis and Financial Ratings | FHTX | US3441741077 - marketscreener.com
Funding Roundup: Silence Therapeutics, AbCellera Announce IPO Pricing, Beyang, Remepy Close Series A Financing - Pharmaceutical Executive
News Flash: Analysts Just Made A Huge Upgrade To Their Foghorn Therapeutics Inc. (NASDAQ:FHTX) Forecasts - simplywall.st
News Flash: Analysts Just Made A Huge Upgrade To Their Foghorn Therapeutics Inc. (NASDAQ:FHTX) Forecasts - simplywall.st
Enterprise value to EBIT forward of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingView
HC Wainwright Issues Negative Outlook for FHTX Earnings - MarketBeat
Foghorn Therapeutics Inc (NASDAQ: FHTX) Stock Price, News & Analysis - kalkine.ca
Foghorn Therapeutics Inc (NASDAQ: FHTX) Stock Price, News & Analysis - Kalkine
Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade - Yahoo Finance
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st
Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade - Zacks Investment Research
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Wall Street Zen Upgrades Foghorn Therapeutics (NASDAQ:FHTX) to Hold - MarketBeat
Foghorn Therapeutics Reports Q2 Results and Pipeline Progress - The Globe and Mail
BTIG Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Discipline and Rules-Based Execution in FHTX Response - Stock Traders Daily
Finanzdaten der Foghorn Therapeutics Inc-Aktie (FHTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):